Show Summary Details
Page of

Breast metastasis from non-small cell lung cancer 

Breast metastasis from non-small cell lung cancer
Breast metastasis from non-small cell lung cancer

Thankamma Ajithkumar

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 28 February 2021

Oligometastatic denotes the presence of a limited metastatic burden. Lung cancer can present synchronous (at diagnosis) or metachronous (at recurrence) oligometastatic disease. Studies show that a subset of oligo-metastatic lung cancer can be treated with a potential curative intent. Recent advances in imaging could identify more patients with oligometastatic disease who will benefit with an aggressive management. Advanced minimally invasive surgery and locally ablative therapy could lead to a better local disease control with minimal side effects. Newer systemic therapy of lung cancer can further enhance the chances of long-term survival. The management of patients with oligometastatic lung cancer should be, thus, individualised based on the extent of disease, and proper assessment of risks and benefits of multimodality treatment.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.